Rathbones Group PLC Has $7.96 Million Stock Position in DexCom, Inc. $DXCM

Rathbones Group PLC lowered its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 13.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 119,891 shares of the medical device company’s stock after selling 18,632 shares during the period. Rathbones Group PLC’s holdings in DexCom were worth $7,957,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. IFP Advisors Inc raised its holdings in shares of DexCom by 131.3% during the fourth quarter. IFP Advisors Inc now owns 2,079 shares of the medical device company’s stock valued at $138,000 after purchasing an additional 1,180 shares during the period. Cullen Frost Bankers Inc. raised its holdings in shares of DexCom by 36.8% during the fourth quarter. Cullen Frost Bankers Inc. now owns 7,020 shares of the medical device company’s stock valued at $466,000 after purchasing an additional 1,890 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new position in shares of DexCom during the fourth quarter valued at about $1,858,000. Profund Advisors LLC raised its holdings in shares of DexCom by 11.0% in the 4th quarter. Profund Advisors LLC now owns 37,289 shares of the medical device company’s stock worth $2,475,000 after acquiring an additional 3,697 shares during the last quarter. Finally, ProShare Advisors LLC raised its holdings in shares of DexCom by 38.5% in the 4th quarter. ProShare Advisors LLC now owns 684,608 shares of the medical device company’s stock worth $45,437,000 after acquiring an additional 190,461 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Trading Up 0.6%

Shares of DXCM stock opened at $71.90 on Friday. The company has a 50 day moving average of $63.46 and a 200-day moving average of $65.94. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $89.98. The firm has a market cap of $27.74 billion, a P/E ratio of 30.73, a PEG ratio of 1.18 and a beta of 1.40.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same quarter last year, the business posted $0.32 EPS. DexCom’s quarterly revenue was up 15.0% compared to the same quarter last year. Sell-side analysts anticipate that DexCom, Inc. will post 2.57 earnings per share for the current year.

Insider Activity at DexCom

In other news, EVP Michael Jon Brown sold 1,700 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $59.91, for a total transaction of $101,847.00. Following the completion of the sale, the executive vice president owned 109,504 shares in the company, valued at $6,560,384.64. This trade represents a 1.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total transaction of $60,730.12. Following the sale, the director owned 25,007 shares of the company’s stock, valued at approximately $1,500,670.07. The trade was a 3.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 6,112 shares of company stock valued at $379,990. 0.28% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

DXCM has been the topic of a number of analyst reports. TD Cowen lowered their target price on shares of DexCom from $84.00 to $75.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Mizuho set a $75.00 target price on shares of DexCom in a report on Friday, May 1st. Robert W. Baird set a $80.00 target price on shares of DexCom in a report on Friday, May 1st. Benchmark initiated coverage on shares of DexCom in a report on Monday, May 11th. They issued a “buy” rating and a $77.00 target price on the stock. Finally, Truist Financial restated a “buy” rating and issued a $80.00 target price (down from $82.00) on shares of DexCom in a report on Tuesday, February 17th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $82.21.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.